- Accueil
- Chercheurs
- Dr Natalie Alméras
Domaine de recherche
Obésité, obésité infantile, activité physique, dépense énergétique, composition corporelle, nutrition, intervention, habitudes de vie, prévention, programmes d'éducation en nutrition, syndrome métabolique, impact des antipsychotiques atypiques sur le profil de risque métabolique.
Description des travaux
L'obésité infantile est une composante de plus en plus importante de l'épidémie d'obésité et a d'importantes conséquences sur la santé des jeunes. On constate maintenant que des maladies autrefois réservées aux adultes font leur apparition de plus en plus tôt dans la vie des jeunes. Bien que l'obésité soit attribuable à différents facteurs, l'augmentation dramatique de cette prévalence est certainement reliée aux changements environnementaux qui affectent nos habitudes de vie. Une équipe dirigée par le Dre Natalie Alméras travaille à l'intégration d'un programme à la formation académique du niveau primaire visant la promotion de saines habitudes de vie chez les enfants. Ce programme d'éducation en nutrition vise à améliorer les connaissances des jeunes et à les inciter à adopter des comportements alimentaires sains. Il est intéressant de souligner que les résultats d'un projet-pilote ont démontré que quelques heures d'intervention en nutrition par année augmente considérablement les connaissances des élèves et permettent de constater un changement significatif dans la qualité de leurs déjeuners et leurs choix de repas, démontrant ainsi l'importance d'agir auprès des jeunes pour augmenter le niveau de leurs connaissances et ainsi leur permettre de faire des choix santé.
Les antipsychotique atypiques sont maintenant la pierre angulaire du traitement de la schizophrénie. Malgré leurs avantages indéniables, leur utilisation est associé à un gain de poids significatif, à des dyslipidémies variées, à des triglycérides élevés et à une intolérance au glucose qui peut dans plusieurs cas mener au diabète de type 2. Ce gain de poids est un déterminant majeur à l'observance à la médication des patients, à une faible estime de soi, à un fonctionnement social diminué et à mauvaise qualité de vie. Le psychiatre est donc confronté à un dilemme où les bienfaits cliniques des antipsychotique atypiques sur la santé mentale peuvent être atténués par l'apparition de complications métaboliques athérogènes. l'équipe du Dre Alméras évalue l'impact des antipsychotiques atypiques sur les composantes de l'équilibre énergétique (apport alimentaire et dépense énergétique). À cet effet, elle s'intéresse notamment aux comportements alimentaires, aux indicateurs de satiété et aux préférence alimentaires. La composition corporelle et la distribution du tissu adipeux font également partie des paramètres étudiés. l'obésité induite par cette médication occasionne également de sérieux désordres métaboliques qui sont au coeur de ses travaux. Toutefois, il est non seulement important d'évaluer de façon adéquate le profil de risque métabolique des patients mais également de les suivre dans le temps et de proposer des programmes d'intervention qui leur sont accessibles, programmes qui permettraient à la fois de réduire le risque de maladie cardiovasculaire et d'obésité et qui influenceraient positivement la santé mentale de cette population.
Publications
93- Couillard C, Bergeron N, Pascot A, Alméras N, Bergeron J, Tremblay A, Prud'homme D, Després JP. Evidence for impaired lipolysis in abdominally obese men: postprandial study of apolipoprotein B-48- and B-100-containing lipoproteins.. Am J Clin Nutr 2002; 76(2):311-8.
- Doucet E, St-Pierre S, Alméras N, Imbeault P, Mauriège P, Pascot A, Després JP, Tremblay A. Reduction of visceral adipose tissue during weight loss.. Eur J Clin Nutr 2002; 56(4):297-304.
- Lemieux I, Alméras N, Mauriège P, Blanchet C, Dewailly E, Bergeron J, Després JP. Prevalence of "hypertriglyceridemic waist" in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors.. Can J Cardiol 2002; 18(7):725-32.
- Doucet E, St-Pierre S, Alméras N, Tremblay A. Relation between appetite ratings before and after a standard meal and estimates of daily energy intake in obese and reduced obese individuals.. Appetite 2003; 40(2):137-43.
- Després JP, Lemieux I, Pascot A, Alméras N, Dumont M, Nadeau A, Bergeron J, Prud'homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.. Arterioscler Thromb Vasc Biol 2003; 23(4):702-3.
- Doucet E, Imbeault P, St-Pierre S, Alméras N, Mauriège P, Després JP, Bouchard C, Tremblay A. Greater than predicted decrease in energy expenditure during exercise after body weight loss in obese men.. Clin Sci (Lond) 2003; 105(1):89-95.
- Couillard C, Vohl MC, Engert JC, Lemieux I, Houde A, Alméras N, Prud'homme D, Nadeau A, Després JP, Bergeron J. Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men.. J Lipid Res 2003; 44(5):986-93.
- Scarsella C, Alméras N, Mauriège P, Blanchet C, Sauvé L, Dewailly E, Bergeron J, Després JP. Prevalence of metabolic alterations predictive of cardiovascular disease risk in the Québec population.. Can J Cardiol 2003; 19(1):51-7.
- Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.. J Clin Psychiatry 2004; 65(4):557-64.
- Alfonzo-González G, Doucet E, Alméras N, Bouchard C, Tremblay A. Estimation of daily energy needs with the FAO/WHO/UNU 1985 procedures in adults: comparison to whole-body indirect calorimetry measurements.. Eur J Clin Nutr 2004; 58(8):1125-31.
- Tremblay AJ, Després JP, Piché ME, Nadeau A, Bergeron J, Alméras N, Tremblay A, Lemieux S. Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome.. Metabolism 2004; 53(3):310-7.
- Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I, Després JP. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.. J Clin Endocrinol Metab 2005; 90(3):1434-9.
- Hins J, Sériès F, Alméras N, Tremblay A. Relationship between severity of nocturnal desaturation and adaptive thermogenesis: preliminary data of apneic patients tested in a whole-body indirect calorimetry chamber.. Int J Obes (Lond) 2006; 30(0):574-7.
- Després JP, Lemieux I, Alméras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity.. Int J Obes (Lond) 2006; 30(0):S44-52.
- Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.. Eur J Clin Pharmacol 2007; 63(2):123-34.
- Côté M, Matias I, Lemieux I, Petrosino S, Alméras N, Després JP, DiMarzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.. Int J Obes 2007; 31(4):692-9.
- Després JP, Poirier P, Bergeron J, Tremblay A, Lemieux I, Alméras N. From individual risk factors and the metabolic syndrome to global cardiometabolic risk.. Eur Heart J Suppl 2008; 10(0):B24-33.
- Metz L, Mercier J, Tremblay A, Alméras N, Joanisse DR. Effect of weight loss on lactate transporter expression in skeletal muscle of obese subjects.. J Appl Physiol 2008; 104(3):633-8.
- Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, Alméras N. Adiposity and eating behaviours in patients under second generation antipsychotics.. Obesity (Silver Spring) 2008; 16(8):1780-7.
- Arsenault BJ, Lachance D, Lemieux I, Alméras N, Tremblay A, Bouchard C, Pérusse L, Després JP. Visceral adipose tissue accumulation, cardiorespiratory fitness, and features of the metabolic syndrome.. Arch Intern Med 2007; 167(14):1518-25.
- Lemieux I, Poirier P, Bergeron J, Almeras N, Lamarche B, Cantin B, Dagenais GR, Després JP. Hypertriglyceridemic waist: A useful screeing phenotype in preventive cardiology?. Can J Cardiol 2007; 23(0):23-31B.
- Després JP, Ross R, Boka G, Alméras N, Lemieux I, . Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.. Arterioscler Thromb Vasc Biol 2009; 29(3):416-23.
- Cartier A, Bergeron J, Poirier P, Alméras N, Tremblay A, Lemieux I, Després JP. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity.. Ann Med 2009; 41(6):471-8.
- Blouin M, Binet M, Bouchard RH, Roy MA, Després JP, Alméras N. Improvement of metabolic risk profile under second-generation antipsychotics: a pilot intervention study.. Can J Psychiatry 2009; 54(4):275-9.
- Blackburn P, Lemieux I, Alméras N, Bergeron J, Côté M, Tremblay A, Lamarche B, Després JP. The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile.. Metabolism 2009; 58(8):1123-30.
- Cartier A, Côté M, Bergeron J, Alméras N, Tremblay A, Lemieux I, Després JP. Plasma soluble tumour necrosis factor-alpha receptor 2 is elevated in obesity: specific contribution of visceral adiposity.. Clin Endocrinol (Oxf) 2010; 72(3):349-57.
- Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors.. Diabetologia 2009; 52(2):213-7.
- Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP, . A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.. Can J Cardiol 2009; 25(9):509-15.
- Borel AL, Boulet G, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Carpentier AC, Després JP.. Improved Plasma FFA/Insulin Homeostasis Is Independently Associated With Improved Glucose Tolerance After a One-Year Lifestyle Intervention in Viscerally Obese Men.. Diabetes Care 2013; 36(10):3254-61.
- Borel AL, Alméras N, Bergeron J, Tremblay A, Poirier P, Després JP. Lactivité physique réduit ladiposité viscérale indépendamment de la perte de poids/Physical activity reduces visceral adipose tissue independently of weight loss.. Méd mal métab 2010; 4(0):143-5.
- Lessard A, Alméras N, Turcotte H, Tremblay A, Després JP, Boulet LP. Adiposity and pulmonary function: Relationship with body fat distribution and systemic inflammation.. Clin Invest Med 2011; 34(2):E64.
- Gilbert JA, Joanisse DR, Chaput JP, Miegueu P, Cianflone K, Alméras N, Tremblay A. Milk supplementation facilitates appetite control in obese women during weight loss: a randomised, single-blind, placebo-controlled trial.. Br J Nutr 2011; 105(1):133-43.
- Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title LM, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY Trial Investigators.. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.. Atherosclerosis 2010; 211(2):565-73.
- Salamin G, Pelletier C, Poirier P, Bertrand OF, Després JP, Alméras N, Costerousse O, Brassard P. Impact of visceral obesity on cardiac parasympathetic activity in type 2 diabetics after coronary artery bypass graft surgery.. Obesity (Silver Spring) 2013; 21(8):1578-85.
- Poliakova N, Després JP, Bergeron J, Alméras N, Tremblay A, Poirier P. Influence of obesity indices, metabolic parameters and age on cardiac autonomic function in abdominally obese men.. Metabolism 2012; 61(9):1270-9.
- Borel AL, Leblanc X, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP, Series F. Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity.. Thorax 2012; 67(8):735-41.
- Smith JD, Borel AL, Nazare JA, Haffner SM, Balkau B, Ross R, Massien C, Alméras N, Després JP. Visceral Adipose Tissue Indicates the Severity of Cardiometabolic Risk in Patients with and without Type 2 Diabetes: Results from the INSPIRE ME IAA Study.. J Clin Endocrinol Metab 2012; 97(5):1517-25.
- Pelletier-Beaumont E, Arsenault BJ, Alméras N, Bergeron J, Tremblay A, Poirier P, Després JP. Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men.. Atherosclerosis 2012; 221(2):577-82.
- Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. Visceral and Not Subcutaneous Abdominal Adiposity Reduction Drives the Benefits of a 1-Year Lifestyle Modification Program.. Obesity (Silver Spring) 2012; 20(6):1223-33.
- Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity.. Metabolism 2012; 61(2):262-72.
- Chandonnet N, Saey D, Alméras N, Marc I. French Pregnancy Physical Activity Questionnaire compared with an accelerometer cut point to classify physical activity among pregnant obese women.. PLoS One 2012; 7(6):e38818.
- Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, Massien C, Alméras N, Després JP. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity.. Am J Clin Nutr 2012; 96(4):714-26.
- Bisson M, Alméras N, Plaisance J, Rhéaume C, Bujold E, Tremblay A, Marc I. Maternal fitness at the onset of the second trimester of pregnancy: correlates and relationship with infant birth weight.. Pediatr Obes 2013; 8(6):464-74.
- Nazare JA, Smith J, Borel AL, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP.. Changes in both global diet quality and physical activity level synergistically reduce visceral adiposity in men with features of metabolic syndrome.. J Nutr 2013; 143(7):1074-83.
- Gaudreault V, Després JP, Rhéaume C, Alméras N, Bergeron J, Tremblay A, Poirier P. Exercise-induced hypertension in men with metabolic syndrome: anthropometric, metabolic, and hemodynamic features.. Metab Syndr Relat Disord 2013; 11(1):7-14.
- Mauriège P, Imbeault P, Doucet E, Lacaille M, Langin D, Alméras N, Després JP, Tremblay A. Weight loss and regain in obese individuals: a link with adipose tissue metabolism indices?. J Physiol Biochem 2013; 69(3):497-505.
- Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.. Diabetes Obes Metab 2013; 15(7):629-41.
- Gaudreault V, Després JP, Rhéaume C, Bergeron J, Alméras N, Tremblay A, Poirier P.. Exercise-induced exaggerated blood pressure response in men with the metabolic syndrome: the role of the autonomous nervous system.. Blood Press Monit 2013; 18(5):252-8.
- Després JP, Alméras N, Gauvin L. Worksite health and wellness programs: Canadian achievements & prospects.. Prog Cardiovasc Dis 2014; 56(5):484-92.
- Villeneuve N, Pelletier-Beaumont E, Nazare JA, Lemieux I, Alméras N, Bergeron J, Tremblay A, Poirier P, Després JP. Interrelationships between changes in anthropometric variables and computed tomography indices of abdominal fat distribution in response to a 1-year physical activity-healthy eating lifestyle modification program in abdominally obese men.. Appl Physiol Nutr Metab 2014; 39(4):503-11.
- Gangloff A, Bergeron J, Pelletier-Beaumont E, Nazare JA, Smith J, Borel AL, Lemieux I, Tremblay A, Poirier P, Alméras N, Després JP. Effect of adipose tissue volume loss on circulating 25-hydroxyvitamin D levels: results from a 1-year lifestyle intervention in viscerally obese men.. Int J Obes (Lond) 2015; 39(11):1638-43.
- Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, Tan CE, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related Cardiometabolic Risk Profile (from the INSPIRE ME IAA Study).. Am J Cardiol 2015; 115(3):307-15.
- Lévesque V, Poirier P, Després JP, Alméras N. Assessing and targeting key lifestyle cardiovascular risk factors at the workplace: Effect on hemoglobin A1c levels.. Ann Med 2015; 47(7):605-14.
- Bisson M, Alméras N, Dufresne SS, Robitaille J, Rhéaume C, Bujold E, Frenette J, Tremblay A, Marc I. A 12-Week Exercise Program for Pregnant Women with Obesity to Improve Physical Activity Levels: An Open Randomised Preliminary Study.. PLoS One 2015; 10(9):e0137742.
- Carter S, Li Z, Lemieux I, Alméras N, Tremblay A, Bergeron J, Poirier P, Deshaies Y, Després JP, Picard F.. Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides.. Atherosclerosis 2014; 237(2):645-51.
- Arsenault BJ, Pelletier-Beaumont E, Alméras N, Tremblay A, Poirier P, Bergeron J, Després JP.. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.. Atherosclerosis 2014; 236(2):321-6.
- Lévesque V, Vallières M, Poirier P, Després JP, Alméras N.. Targeting Abdominal Adiposity and Cardiorespiratory Fitness in the Workplace.. Med Sci Sports Exerc 2015; 47(7):1342-50.
- Punthakee Z, Alméras N, Després JP, Dagenais GR, Anand SS, Hunt DL, Sharma AM, Jung H, Yusuf S, Gerstein HC. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.. Diabet Med 2014; 31(9):1086-92.
- Borel AL, Nazare JA, Smith J, Aschner P, Barter P, Van Gaal L, Eng Tan C, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance.. Int J Obes (Lond) 2015; 39(3):495-501.
- Boyer M, Mitchell PL, Poirier P, Alméras N, Tremblay A, Bergeron J, Després JP, Arsenault BJ. Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia.. Am J Physiol Endocrinol Metab 2018; 315(4):E460-E468.
- Le Bodo Y, Paquette MC, Vallières M, Alméras N. Is Sugar the new Tobacco? Insights from Laboratory Studies, Consumer Surveys and Public Health.. Curr Obes Rep 2015; 4(1):111-21.
- Matikainen N, Björnson E, Söderlund S, Borén C, Eliasson B, Pietiläinen KH, Bogl LH, Hakkarainen A, Lundbom N, Rivellese A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.. PLoS One 2016; 11(1):e0145890.
- Leclerc J, Arsenault M, Després JP, Brassard P, Gaudreault V, Bergeron J, Alméras N, Tremblay A, Auclair A, Ross MK, Denault-Bissonnette S, Poirier P. Determinants of Improvement In Left Ventricular Diastolic Function Following a 1-Year Lifestyle Modification Program in Abdominally Obese Men with Features of the Metabolic Syndrome.. Metab Syndr Relat Disord 2016; 14(10):483-491.
- Grenier A, Brassard P, Bertrand OF, Després JP, Costerousse O, Alméras N, Poirier P. Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.. Clin Auton Res 2016; 26(6):407-14.
- Martin M, Almeras N, Després JP, Coxson HO, Washko GR, Vivodtzev I, Wouters EF, Rutten E, Williams MC, Murchison JT, MacNee W, Sin DD, Maltais F. Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy.. Int J Chron Obstruct Pulmon Dis 2017; 12(0):451-460.
- Borel AL, Nazare JA, Baillot A, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. Cardiometabolic risk improvement in response to a 3-yr lifestyle modification program in men: contribution of improved cardiorespiratory fitness vs. weight loss.. Am J Physiol Endocrinol Metab 2017; 312(4):E273-E281.
- Matikainen N, Söderlund S, Björnson E, Bogl LH, Pietiläinen KH, Hakkarainen A, Lundbom N, Eliasson B, Räsänen SM, Rivellese A, Patti L, Prinster A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR. Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.. Nutr Metab Cardiovasc Dis 2017; 27(6):534-542.
- Lévesque V, Poirier P, Després JP, Alméras N. Relation Between a Simple Lifestyle Risk Score and Established Biological Risk Factors for Cardiovascular Disease.. Am J Cardiol 2017; 120(11):1939-1946.
- Gourlan M, Takito M, Lambert C, Fregeac B, Alméras N, Coste O, Pereira B, Cousson-Gélie F. Impact and Moderating Variables of an Intervention Promoting Physical Activity Among Children: Results From a Pilot Study.. Int Q Community Health Educ 2018; 38(3):195-203.
- Côté CE, Rhéaume C, Poirier P, Després JP, Alméras N. Deteriorated Cardiometabolic Risk Profile in Individuals With Excessive Blood Pressure Response to Submaximal Exercise.. Am J Hypertens 2019; 32(10):945-952.
- Taskinen MR, Söderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietiläinen KH, Räsänen S, Lundbom N, Björnson E, Eliasson B, Mancina RM, Romeo S, Alméras N, Pepa GD, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Després JP, Borén J.. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.. J Intern Med 2017; 282(2):187-201.
- LeBlanc S, Coulombe F, Bertrand OF, Bibeau K, Pibarot P, Marette A, Alméras N, Lemieux I, Després JP, Larose E.. Hypertriglyceridemic Waist: A Simple Marker of High-Risk Atherosclerosis Features Associated With Excess Visceral Adiposity/Ectopic Fat.. J Am Heart Assoc 2018; 7(8):e008139.
- Maltais A, Alméras N, Lemieux I, Tremblay A, Bergeron J, Poirier P, Després JP.. Trunk muscle quality assessed by computed tomography: Association with adiposity indices and glucose tolerance in men. Metabolism 2018; 85(0):205-212.
- Coats V, Després JP, Alméras N, Martin M, Sin DD, Rabasa-Lhoret R, Larose E, Tan WC, Bourbeau J, Maltais F. Ectopic adiposity and cardiometabolic health in COPD.. Int J Chron Obstruct Pulmon Dis 2018; 13(0):3331-3340.
- Carter S, Lemieux I, Li Z, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP, Picard F. Changes in IGFBP-2 levels following a one-year lifestyle modification program are independently related to improvements in plasma apo B and LDL apo B levels.. Atherosclerosis 2019; 281(0):89-97.
- Nolin MA, Demers MF, Rauzier C, Bouchard RH, Cadrin C, Després JP, Roy MA, Alméras N, Picard F. Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.. World J Biol Psychiatry 2021; 22(3):175-182.
- Maltais A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. One-Year Lifestyle Intervention, Muscle Lipids, and Cardiometabolic Risk.. Med Sci Sports Exerc 2019; 51(10):2156-2165.
- Buteau-Poulin D, Poirier P, Després JP, Alméras N. Assessing nutritional quality as a 'vital sign' of cardiometabolic health.. Br J Nutr 2019; 122(2):195-205.
- Gangloff A, Bergeron J, Lemieux I, Tremblay A, Poirier P, Alméras N, Després JP. Relationships between circulating 25(OH) vitamin D, leptin levels and visceral adipose tissue volume: results from a 1-year lifestyle intervention program in men with visceral obesity.. Int J Obes (Lond) 2020; 44(2):280-288.
- Viglino D, Martin M, Almeras N, Després JP, Coxson HO, Pépin JL, Vivodtzev I, Maltais F; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.. Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis.. Int J Chron Obstruct Pulmon Dis 2019; 14(0):3053-3061.
- Viglino D, Martin M, Piché ME, Brouillard C, Després JP, Alméras N, Tan WC, Coats V, Bourbeau J, Pépin JL, Maltais F. Metabolic profiles among COPD and controls in the CanCOLD population-based cohort.. PLoS One 2020; 15(4):e0231072.
- Chartrand DJ, Larose E, Poirier P, Mathieu P, Alméras N, Pibarot P, Lamarche B, Rhéaume C, Després JP. Visceral adiposity and liver fat as mediators of the association between cardiorespiratory fitness and plasma glucose-insulin homeostasis.. Am J Physiol Endocrinol Metab 2020; 319(3):E548-E556.
- Gallani MC, Proulx-Belhumeur A, Alméras N, Després JP, Doré M, Giguère JF.. Development and Validation of a Salt Food Frequency Questionnaire (FFQ-Na) and a Discretionary Salt Questionnaire (DSQ) for the Evaluation of Salt Intake among French-Canadian Population.. Nutrients 2020; 13(1):105.
- Bordeleau M, Leduc G, Blanchet C, Drapeau V, Alméras N. Body Size Misperception and Dissatisfaction in Elementary School Children.. Child Obes 2021; 17(7):467-475.
- Amil S, Lemieux I, Poirier P, Lamarche B, Després JP, Alméras N. Targeting Diet Quality at the Workplace: Influence on Cardiometabolic Risk.. Nutrients 2021; 13(7):2283.
- Pelletier C, Gagnon MP, Alméras N, Després JP, Poirier P, Tremblay A, Chabot C, Rhéaume C. Using an activity tracker to increase motivation for physical activity in patients with type 2 diabetes in primary care: a randomized pilot trial.. Mhealth 2021; 7(0):59.
- Chartrand DJ, Murphy-Després A, Alméras N, Lemieux I, Larose E, Després JP. Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat.. Curr Atheroscler Rep 2022; 24(4):185-195.
- Bordeleau M, Gilbert JA, Alméras N, Monthuy-Blanc J, Gagnon J, Mathieu MÈ, Drapeau V. Body image and health-related behaviors among fitspirit participants.. BMC Public Health 2022; 22(1):1764.
- Bordeleau M, Alméras N, Panahi S, Drapeau V. Body Image and Lifestyle Behaviors in High School Adolescents.. Children (Basel) 2023; 10(7):1263.
- Edimo Dikobo SJ, Lemieux I, Poirier P, Després JP, Alméras N. Leisure-time physical activity is more strongly associated with cardiometabolic risk than occupational physical activity: Results from a workplace lifestyle modification program.. Prog Cardiovasc Dis 2023; 78(0):74-82.
- Rauzier C, Chartrand DJ, Alméras N, Lemieux I, Larose E, Mathieu P, Pibarot P, Lamarche B, Rhéaume C, Poirier P, Després JP, Picard F. Associations of insulin-like growth factor binding protein-2 (IGFBP-2) with metabolic profile and hepatic fat deposition in asymptomatic men and women.. Am J Physiol Endocrinol Metab 2023; 325(1):E99-E105.
- Bordeleau M, Purcell M, Provencher V, Panahi S, Jacob R, Alméras N, Drapeau V. Impact of a Web-Based Nutrition Intervention on Eating Behaviors and Body Size Preoccupations among Adolescents.. Children (Basel) 2023; 10(11):1736.
- Rauzier C, Chartrand DJ, Alméras N, Lemieux I, Larose E, Mathieu P, Pibarot P, Lamarche B, Rhéaume C, Poirier P, Després JP, Picard F. Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity.. Front Endocrinol (Lausanne) 2023; 14(0):1222101.